RCUS Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Arcus Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.44 |
| 52 Week High | US$20.31 |
| 52 Week Low | US$12.95 |
| Beta | 0.88 |
| 11 Month Change | 11.89% |
| 3 Month Change | 27.44% |
| 1 Year Change | 14.39% |
| 33 Year Change | -47.81% |
| 5 Year Change | 127.09% |
| Change since IPO | 8.47% |
Recent News & Updates
Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones
Sep 23Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 15
Recent updates
Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones
Sep 23Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business
Aug 19Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
May 15Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts
May 13Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money
May 10We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers
May 12Shareholder Returns
| RCUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | 0.6% | 0.8% |
| 1Y | 14.4% | 27.4% | 38.4% |
Return vs Industry: RCUS underperformed the US Biotechs industry which returned 27.4% over the past year.
Return vs Market: RCUS underperformed the US Market which returned 38.4% over the past year.
Price Volatility
| RCUS volatility | |
|---|---|
| RCUS Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RCUS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RCUS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 577 | Terry Rosen | www.arcusbio.com |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease.
Arcus Biosciences, Inc. Fundamentals Summary
| RCUS fundamental statistics | |
|---|---|
| Market cap | US$1.69b |
| Earnings (TTM) | -US$249.00m |
| Revenue (TTM) | US$247.00m |
6.8x
P/S Ratio-6.8x
P/E RatioIs RCUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCUS income statement (TTM) | |
|---|---|
| Revenue | US$247.00m |
| Cost of Revenue | US$342.00m |
| Gross Profit | -US$95.00m |
| Other Expenses | US$154.00m |
| Earnings | -US$249.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.72 |
| Gross Margin | -38.46% |
| Net Profit Margin | -100.81% |
| Debt/Equity Ratio | 3.1% |
How did RCUS perform over the long term?
See historical performance and comparison